Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017

JAMA. 2019 Jul 16;322(3):267-269. doi: 10.1001/jama.2019.7521.


This study characterizes price increases exceeding inflation between 2012 and 2017 for protected-class drugs (antineoplastics, antiretrovirals, antidepressants, antipsychotics, anticonvulsants, and immunosuppressants for transplant patients) that would lead to their exclusion from Medicare Part D coverage based on excessive cost under a 2018 CMS rule intended to facilitate more effective price negotiations.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Drug Costs / trends*
  • Inflation, Economic*
  • Insurance Coverage
  • Medicare Part D / economics*
  • Patents as Topic
  • Prescription Drugs / economics*
  • United States


  • Prescription Drugs